Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

@article{Hallek2010AdditionOR,
  title={Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial},
  author={M. Hallek and K. Fischer and G. Fingerle-Rowson and A. Fink and the German Chronic Lymphocytic Leukaemia Study Group},
  journal={The Lancet},
  year={2010},
  volume={376},
  pages={1164-1174}
}
BACKGROUND On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia. METHODS Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of… CONTINUE READING
1,579 Citations

Paper Mentions

Interventional Clinical Trial
Study Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients with Early Stage CLL With High Risk of Early Disease Progression. The study… Expand
ConditionsChronic Lymphocytic Leukemia- Binet Staging System
InterventionDrug
Interventional Clinical Trial
In previously-untreated subjects with CLL, fludarabine and rituximab with or without cyclophosphamide (FR or FCR) produces complete responses (CR) of 40-80%. The major complication… Expand
ConditionsChronic Lymphocytic Leukemia (CLL)
InterventionDrug
Interventional Clinical Trial
The investigators would like to propose a phase-2 prospective multicenter trial evaluating the efficacy of rituximab combination with our current chemotherapy strategy for adult Acute… Expand
ConditionsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
InterventionDrug
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
  • K. Fischer, P. Cramer, +17 authors C. Wendtner
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
  • 345
  • PDF
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
  • K. Fischer, P. Cramer, +20 authors C. Wendtner
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
  • 368
  • PDF
Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial
  • S. Molica
  • Medicine
  • Expert review of anticancer therapy
  • 2011
  • 12
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
  • 4
  • PDF

References

SHOWING 1-10 OF 41 REFERENCES
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
  • W. Wierda, S. O'brien, +13 authors M. Keating
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
  • 522
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
  • I. Flinn, D. Neuberg, +8 authors M. Tallman
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
  • 272
  • PDF
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
  • 939
  • PDF
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
  • 608